LungLife AI, INC VA sites in validation study; SAB appointment (0437F)
March 17 2022 - 3:00AM
UK Regulatory
TIDMLLAI
RNS Number : 0437F
LungLife AI, INC
17 March 2022
LungLife AI, Inc.
(the "Company" or "LungLife")
Veterans Affairs (VA) sites added to validation study with first
Veteran enroled
Key lung cancer specialist, Dr Drew Moghanaki, appointed to
Scientific Advisory Board
LungLife AI (AIM: LLAI), a developer of clinical diagnostic
solutions for lung cancer, announces its pivotal clinical study to
evaluate the LungLB(R) test will now include multiple VA medical
centres, of which the first participant has been enroled from the
Bay Pines VA in Florida.
The VA has the United States' largest integrated health care
system, providing care at nearly 1,300 facilities and serving 9
million veterans each year. Lung cancer is the leading cause of
cancer-related deaths among US veterans, and it is believed that
veterans are at higher risk in part due to environmental exposures
during military service. An estimated 900,000 US veterans are
at-risk for lung cancer, and VA hospitals diagnose around 7,700 new
lung cancer cases each year.
The Company also announces the appointment of Dr Drew Moghanaki,
MD, MPH, to its Scientific Advisory Board, who is an
internationally recognised lung cancer specialist. He is Professor
and Chief of Thoracic Oncology at the UCLA Department of Radiation
Oncology. Dr Moghanaki brings extensive leadership to the
Scientific Advisory Board as the Director of the VA Partnership to
increase Access to Lung Cancer Screening programme (VA-PALS), and
the co-chair of the VA Lung Cancer Surgery or Stereotactic
Radiotherapy (VALOR) Phase III study, investigating treatment
options for stage I lung cancer. Dr Moghanaki is also Staff
Physician at the Greater Los Angeles VA Healthcare System.
Dr Drew Moghanaki, MD, MPH, Scientific Advisory Board member at
LungLife, said: "Blood-based testing to facilitate early detection
of lung cancer would be a welcomed advance as the majority of lung
cancers continue to be diagnosed in later stages. I am pleased to
be joining LungLife's Scientific Advisory Board and look forward to
working with them to unlock the full potential of the LungLB(R)
test."
Paul Pagano, Chief Executive Officer of LungLife, said : "I am
delighted that we will have representation from the VA Healthcare
System in our study, as this marks an important step on our journey
towards the successful deployment of the LungLB(R) test. Dr
Moghanaki brings with him significant experience in early detection
and treatment of lung cancer which will further strengthen our
Scientific Advisory Board."
For further information please contact:
LungLife AI, Inc. www.lunglifeai.com
Paul Pagano, CEO Via Walbrook PR
David Anderson, CFO
Investec Bank plc (Nominated Adviser Tel: +44 (0)20 7597 5970
& Broker)
Daniel Adams / Virginia Bull / Cameron
MacRitchie
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or LungLifeAI@walbrookpr.com
Paul McManus / Alice Woodings / Phillip Mob: 07980 541 893 / 07407 804 654 /
Marriage 0 7867 984 082
About Lunglife AI
LungLife AI is a developer of clinical diagnostic solutions
designed to make a significant impact in the early detection of
lung cancer, the deadliest cancer globally. Using a minimally
invasive blood draw, the Company's LungLB(R) test is designed to
deliver additional information to clinicians who are evaluating
indeterminate lung nodules. For more information visit
www.lunglifeai.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCUNABRUAUOAAR
(END) Dow Jones Newswires
March 17, 2022 03:00 ET (07:00 GMT)
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From May 2024 to Jun 2024
Lunglife Ai (LSE:LLAI)
Historical Stock Chart
From Jun 2023 to Jun 2024